| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 5.50 | 0.03 (+0.55%) | 3.85 - 5.69 | 151.2 thousand (Below Avg) |
Market data as of 2:10PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 5.36 |
|---|---|
| Previous Close | 5.47 |
| Day's Range | 5.36 - 5.59 |
| Market Cap | 184.9M |
| Avg Volume (10 Day) | 259.6K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.52 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Targacept Reports First Quarter 2013 Financial Results
Business Wire - Tuesday 05/07/2013 7:35 AM ET
Targacept to Report First Quarter 2013 Financial Results on May 7, 2013
Business Wire - Tuesday 04/30/2013 8:55 AM ET
Targacept Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer’s Disease
Business Wire - Monday 04/29/2013 8:55 AM ET
Targacept Announces Participation in Upcoming Conferences
Business Wire - Monday 04/22/2013 4:05 PM ET
| TRGT | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -52.71% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.01 | |
| LT Debt/Equity | 0.01 | |
| Earnings Yield | -- | |
| Price/Sales | 4.77 |
| Company | Last | Change |
|---|---|---|
| Alcobra Ltd | 7.40 | -1.99% |
| Sinovac Biotech Ltd | 3.36 | +0.30% |
| Pluristem Therapeutics Inc | 3.06 | -2.86% |
| Durata Therapeutics Inc | 7.01 | +1.01% |
| Acasti Pharma Inc | 2.56 | +2.40% |
Data is delayed by at least 15 min.